 Brian Kavanagh
Concepts (624)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 81 | 2023 | 299 | 12.630 |
Why?
| | Radiation Oncology | 28 | 2022 | 75 | 6.950 |
Why?
| | Lung Neoplasms | 59 | 2023 | 2159 | 4.230 |
Why?
| | Prostatic Neoplasms | 29 | 2020 | 913 | 3.620 |
Why?
| | Brain Neoplasms | 34 | 2023 | 966 | 3.420 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 28 | 2023 | 959 | 2.810 |
Why?
| | Radiotherapy | 17 | 2016 | 175 | 2.640 |
Why?
| | Liver Neoplasms | 21 | 2019 | 504 | 2.610 |
Why?
| | Neoplasms | 28 | 2021 | 2086 | 2.360 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 30 | 2023 | 117 | 2.130 |
Why?
| | Radiotherapy Dosage | 44 | 2023 | 243 | 2.020 |
Why?
| | Radiotherapy, Conformal | 17 | 2017 | 68 | 1.970 |
Why?
| | Radiation Injuries | 16 | 2018 | 128 | 1.900 |
Why?
| | Glioblastoma | 12 | 2016 | 250 | 1.890 |
Why?
| | Radiotherapy, Intensity-Modulated | 16 | 2019 | 124 | 1.890 |
Why?
| | Small Cell Lung Carcinoma | 6 | 2023 | 77 | 1.640 |
Why?
| | Four-Dimensional Computed Tomography | 7 | 2021 | 25 | 1.500 |
Why?
| | Cranial Irradiation | 7 | 2020 | 66 | 1.490 |
Why?
| | Cone-Beam Computed Tomography | 9 | 2023 | 24 | 1.380 |
Why?
| | Brachytherapy | 14 | 2016 | 100 | 1.380 |
Why?
| | Dacarbazine | 9 | 2016 | 99 | 1.290 |
Why?
| | Humans | 216 | 2023 | 114043 | 1.190 |
Why?
| | Pulmonary Ventilation | 5 | 2021 | 72 | 1.190 |
Why?
| | Aged | 97 | 2023 | 18969 | 1.190 |
Why?
| | Chemoradiotherapy | 8 | 2020 | 187 | 1.130 |
Why?
| | Antineoplastic Agents, Alkylating | 6 | 2016 | 68 | 1.130 |
Why?
| | Societies, Medical | 9 | 2021 | 655 | 1.110 |
Why?
| | Radiotherapy, Adjuvant | 8 | 2015 | 182 | 1.080 |
Why?
| | Middle Aged | 100 | 2023 | 26605 | 1.010 |
Why?
| | Aged, 80 and over | 52 | 2020 | 6306 | 0.950 |
Why?
| | Uterine Cervical Neoplasms | 9 | 2016 | 213 | 0.900 |
Why?
| | SEER Program | 10 | 2018 | 195 | 0.900 |
Why?
| | Neoplasm Metastasis | 10 | 2020 | 521 | 0.860 |
Why?
| | Neoplasm Recurrence, Local | 14 | 2014 | 850 | 0.850 |
Why?
| | Male | 109 | 2023 | 55396 | 0.840 |
Why?
| | Radiation Oncologists | 2 | 2022 | 4 | 0.830 |
Why?
| | Radiation Pneumonitis | 6 | 2021 | 24 | 0.810 |
Why?
| | Neoplasm Staging | 24 | 2018 | 1162 | 0.800 |
Why?
| | Radiometry | 10 | 2022 | 41 | 0.790 |
Why?
| | Databases, Factual | 10 | 2017 | 1125 | 0.790 |
Why?
| | Internship and Residency | 5 | 2022 | 920 | 0.790 |
Why?
| | Dose-Response Relationship, Radiation | 20 | 2021 | 127 | 0.770 |
Why?
| | Registries | 5 | 2018 | 1764 | 0.760 |
Why?
| | Whole-Body Irradiation | 4 | 2020 | 72 | 0.750 |
Why?
| | Neoplasm Grading | 6 | 2016 | 241 | 0.740 |
Why?
| | Social Media | 2 | 2020 | 131 | 0.740 |
Why?
| | United States | 31 | 2022 | 12137 | 0.730 |
Why?
| | Liver | 9 | 2018 | 1633 | 0.720 |
Why?
| | Medicine | 2 | 2021 | 102 | 0.700 |
Why?
| | Videoconferencing | 1 | 2020 | 57 | 0.690 |
Why?
| | Travel | 1 | 2020 | 121 | 0.660 |
Why?
| | Carcinoma, Squamous Cell | 8 | 2007 | 577 | 0.660 |
Why?
| | Scattering, Radiation | 5 | 2022 | 94 | 0.660 |
Why?
| | Female | 97 | 2023 | 59325 | 0.650 |
Why?
| | Radiation | 1 | 2019 | 24 | 0.650 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2009 | 140 | 0.640 |
Why?
| | Respiratory Function Tests | 3 | 2023 | 522 | 0.640 |
Why?
| | Models, Economic | 1 | 2019 | 48 | 0.640 |
Why?
| | Breast Neoplasms | 11 | 2022 | 1846 | 0.630 |
Why?
| | Carcinoma, Renal Cell | 5 | 2015 | 168 | 0.630 |
Why?
| | Combined Modality Therapy | 24 | 2019 | 1117 | 0.630 |
Why?
| | Treatment Outcome | 32 | 2023 | 9049 | 0.630 |
Why?
| | Astrocytoma | 4 | 2014 | 106 | 0.620 |
Why?
| | Kidney Neoplasms | 6 | 2015 | 324 | 0.620 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2019 | 88 | 0.620 |
Why?
| | Adult | 68 | 2023 | 30375 | 0.610 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2019 | 152 | 0.600 |
Why?
| | Faculty, Medical | 1 | 2020 | 226 | 0.600 |
Why?
| | Lung | 10 | 2023 | 3521 | 0.590 |
Why?
| | Stereotaxic Techniques | 3 | 2006 | 29 | 0.580 |
Why?
| | Antineoplastic Agents | 13 | 2023 | 1875 | 0.560 |
Why?
| | Prostate-Specific Antigen | 8 | 2016 | 150 | 0.550 |
Why?
| | Neoplasms, Second Primary | 2 | 2008 | 92 | 0.540 |
Why?
| | Quality of Life | 6 | 2021 | 2343 | 0.540 |
Why?
| | Preoperative Care | 1 | 2018 | 319 | 0.540 |
Why?
| | Radiotherapy, Computer-Assisted | 6 | 2015 | 12 | 0.520 |
Why?
| | Models, Biological | 8 | 2018 | 1611 | 0.510 |
Why?
| | Insurance Coverage | 4 | 2019 | 199 | 0.510 |
Why?
| | Organs at Risk | 5 | 2021 | 30 | 0.500 |
Why?
| | Prospective Studies | 22 | 2023 | 6195 | 0.500 |
Why?
| | Androgen Antagonists | 6 | 2020 | 69 | 0.490 |
Why?
| | Disease-Free Survival | 12 | 2019 | 618 | 0.480 |
Why?
| | Magnetic Resonance Imaging | 9 | 2023 | 3039 | 0.480 |
Why?
| | Oligodendroglioma | 1 | 2014 | 15 | 0.480 |
Why?
| | Observational Studies as Topic | 1 | 2015 | 90 | 0.460 |
Why?
| | Radiation Tolerance | 6 | 2015 | 92 | 0.460 |
Why?
| | Immunologic Factors | 1 | 2016 | 217 | 0.460 |
Why?
| | Clinical Trials as Topic | 9 | 2017 | 926 | 0.460 |
Why?
| | Health Physics | 2 | 2016 | 4 | 0.450 |
Why?
| | Checklist | 1 | 2015 | 84 | 0.450 |
Why?
| | Perfusion Imaging | 1 | 2014 | 51 | 0.450 |
Why?
| | Beauty | 1 | 2013 | 11 | 0.450 |
Why?
| | Protein Kinase Inhibitors | 6 | 2019 | 784 | 0.450 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2019 | 1356 | 0.440 |
Why?
| | Retrospective Studies | 34 | 2023 | 12521 | 0.430 |
Why?
| | Phantoms, Imaging | 5 | 2023 | 123 | 0.430 |
Why?
| | Spiral Cone-Beam Computed Tomography | 2 | 2023 | 3 | 0.430 |
Why?
| | Artifacts | 4 | 2019 | 114 | 0.430 |
Why?
| | ErbB Receptors | 10 | 2023 | 554 | 0.430 |
Why?
| | Medicare | 4 | 2021 | 661 | 0.430 |
Why?
| | Oxygen | 5 | 2016 | 851 | 0.420 |
Why?
| | Credentialing | 1 | 2012 | 12 | 0.420 |
Why?
| | Liver Regeneration | 2 | 2012 | 29 | 0.420 |
Why?
| | Kaplan-Meier Estimate | 11 | 2019 | 813 | 0.410 |
Why?
| | Proton Therapy | 2 | 2015 | 10 | 0.410 |
Why?
| | Survival Analysis | 11 | 2020 | 1206 | 0.400 |
Why?
| | Follow-Up Studies | 18 | 2019 | 4392 | 0.390 |
Why?
| | Antibodies | 2 | 2018 | 365 | 0.390 |
Why?
| | Hemoglobin A | 2 | 2002 | 21 | 0.390 |
Why?
| | Rectum | 4 | 2014 | 151 | 0.380 |
Why?
| | Consensus | 4 | 2022 | 532 | 0.380 |
Why?
| | Survival Rate | 13 | 2019 | 1638 | 0.380 |
Why?
| | Lymph Nodes | 1 | 2014 | 415 | 0.380 |
Why?
| | Carcinoma | 2 | 2006 | 198 | 0.370 |
Why?
| | Relative Biological Effectiveness | 2 | 2008 | 3 | 0.370 |
Why?
| | Prognosis | 15 | 2020 | 3315 | 0.350 |
Why?
| | Erlotinib Hydrochloride | 4 | 2019 | 64 | 0.350 |
Why?
| | Radiotherapy, High-Energy | 2 | 2008 | 12 | 0.350 |
Why?
| | Comparative Effectiveness Research | 1 | 2011 | 131 | 0.350 |
Why?
| | Skin Neoplasms | 2 | 2015 | 754 | 0.350 |
Why?
| | Antigens, Neoplasm | 3 | 2009 | 222 | 0.340 |
Why?
| | Neoplastic Stem Cells | 1 | 2013 | 327 | 0.340 |
Why?
| | Proportional Hazards Models | 9 | 2019 | 1078 | 0.330 |
Why?
| | Stomach | 1 | 2010 | 102 | 0.330 |
Why?
| | Positron-Emission Tomography | 6 | 2019 | 260 | 0.330 |
Why?
| | Career Choice | 2 | 2021 | 178 | 0.330 |
Why?
| | Antigens, CD | 2 | 2009 | 440 | 0.320 |
Why?
| | Intestine, Small | 1 | 2010 | 121 | 0.320 |
Why?
| | Cell Hypoxia | 3 | 2002 | 221 | 0.320 |
Why?
| | Risk Assessment | 4 | 2015 | 2958 | 0.310 |
Why?
| | Head and Neck Neoplasms | 3 | 2008 | 427 | 0.310 |
Why?
| | Respiratory Mechanics | 1 | 2008 | 56 | 0.300 |
Why?
| | Receptor Protein-Tyrosine Kinases | 4 | 2015 | 224 | 0.300 |
Why?
| | Medical Oncology | 3 | 2020 | 229 | 0.300 |
Why?
| | Quinazolines | 6 | 2014 | 240 | 0.300 |
Why?
| | Vision, Ocular | 1 | 2008 | 30 | 0.290 |
Why?
| | Radiation Protection | 2 | 2009 | 34 | 0.290 |
Why?
| | Orbit | 1 | 2008 | 52 | 0.290 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2008 | 53 | 0.290 |
Why?
| | Colorectal Neoplasms | 4 | 2017 | 592 | 0.290 |
Why?
| | Pyrazoles | 4 | 2021 | 361 | 0.290 |
Why?
| | Pyridines | 4 | 2021 | 419 | 0.280 |
Why?
| | Spinal Neoplasms | 2 | 2007 | 26 | 0.280 |
Why?
| | Bone Neoplasms | 4 | 2019 | 191 | 0.280 |
Why?
| | Prostatectomy | 3 | 2014 | 97 | 0.280 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2007 | 22 | 0.280 |
Why?
| | Linear Models | 2 | 2010 | 768 | 0.280 |
Why?
| | Algorithms | 7 | 2017 | 1469 | 0.270 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2006 | 29 | 0.270 |
Why?
| | Radiation-Sensitizing Agents | 3 | 2001 | 38 | 0.270 |
Why?
| | Patient Selection | 3 | 2021 | 629 | 0.270 |
Why?
| | Melanoma | 3 | 2018 | 620 | 0.270 |
Why?
| | Urologic Diseases | 1 | 2006 | 35 | 0.270 |
Why?
| | Cancer Vaccines | 1 | 2007 | 137 | 0.270 |
Why?
| | Time Factors | 9 | 2021 | 6077 | 0.260 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2007 | 170 | 0.260 |
Why?
| | Glomus Jugulare Tumor | 1 | 2006 | 5 | 0.260 |
Why?
| | Tumor Burden | 9 | 2014 | 258 | 0.260 |
Why?
| | Immunotherapy, Adoptive | 1 | 2007 | 184 | 0.250 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2008 | 337 | 0.250 |
Why?
| | Necrosis | 4 | 2022 | 209 | 0.250 |
Why?
| | Central Nervous System | 3 | 2023 | 230 | 0.250 |
Why?
| | Practice Guidelines as Topic | 5 | 2021 | 1381 | 0.250 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2008 | 196 | 0.250 |
Why?
| | Lymphocyte Activation | 2 | 2009 | 1036 | 0.250 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 334 | 0.240 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2007 | 210 | 0.240 |
Why?
| | Tomography, X-Ray Computed | 11 | 2015 | 2272 | 0.240 |
Why?
| | Insurance, Health | 2 | 2018 | 243 | 0.240 |
Why?
| | Coronavirus Infections | 2 | 2020 | 326 | 0.240 |
Why?
| | CTLA-4 Antigen | 3 | 2018 | 76 | 0.240 |
Why?
| | Data Mining | 2 | 2016 | 100 | 0.240 |
Why?
| | Signal-To-Noise Ratio | 3 | 2019 | 56 | 0.240 |
Why?
| | Dendritic Cells | 1 | 2007 | 435 | 0.230 |
Why?
| | Particle Accelerators | 3 | 2019 | 9 | 0.230 |
Why?
| | Propionates | 2 | 2001 | 34 | 0.220 |
Why?
| | Rectal Neoplasms | 4 | 2008 | 122 | 0.220 |
Why?
| | Chemotherapy, Adjuvant | 7 | 2015 | 332 | 0.220 |
Why?
| | Aniline Compounds | 2 | 2001 | 70 | 0.220 |
Why?
| | Molecular Targeted Therapy | 2 | 2016 | 347 | 0.210 |
Why?
| | Oncogene Addiction | 1 | 2023 | 5 | 0.210 |
Why?
| | Radiopharmaceuticals | 3 | 2014 | 158 | 0.210 |
Why?
| | Inappropriate ADH Syndrome | 2 | 1993 | 7 | 0.210 |
Why?
| | Nasopharyngeal Neoplasms | 2 | 1993 | 13 | 0.210 |
Why?
| | Propensity Score | 4 | 2018 | 225 | 0.210 |
Why?
| | Radiography | 6 | 2014 | 803 | 0.200 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2008 | 959 | 0.200 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2013 | 115 | 0.200 |
Why?
| | Pandemics | 2 | 2020 | 1310 | 0.200 |
Why?
| | Analysis of Variance | 4 | 2016 | 1218 | 0.190 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2023 | 393 | 0.190 |
Why?
| | Pelvis | 3 | 2023 | 89 | 0.190 |
Why?
| | Mass Screening | 1 | 2008 | 979 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2021 | 27 | 0.190 |
Why?
| | Erythropoietin | 1 | 2001 | 72 | 0.180 |
Why?
| | Lymphatic Metastasis | 3 | 2019 | 275 | 0.180 |
Why?
| | National Cancer Institute (U.S.) | 2 | 2017 | 40 | 0.180 |
Why?
| | Gene Rearrangement | 3 | 2018 | 135 | 0.180 |
Why?
| | Pyrimidines | 2 | 2021 | 374 | 0.180 |
Why?
| | Palatal Neoplasms | 1 | 2000 | 4 | 0.170 |
Why?
| | Anemia | 1 | 2001 | 143 | 0.170 |
Why?
| | Technology, Radiologic | 2 | 2010 | 6 | 0.170 |
Why?
| | Adenocarcinoma | 4 | 2008 | 787 | 0.170 |
Why?
| | Radiographic Image Enhancement | 1 | 2000 | 52 | 0.170 |
Why?
| | Proto-Oncogene Proteins | 2 | 2023 | 607 | 0.170 |
Why?
| | Erythrocyte Transfusion | 1 | 2001 | 161 | 0.170 |
Why?
| | Electromagnetic Phenomena | 1 | 2019 | 20 | 0.170 |
Why?
| | Pelvic Neoplasms | 1 | 1999 | 18 | 0.170 |
Why?
| | Relative Value Scales | 1 | 2019 | 5 | 0.170 |
Why?
| | Suggestion | 1 | 2019 | 5 | 0.170 |
Why?
| | Cohort Studies | 4 | 2018 | 4883 | 0.170 |
Why?
| | Fluoroscopy | 1 | 2000 | 139 | 0.170 |
Why?
| | Thoracic Neoplasms | 3 | 2015 | 31 | 0.170 |
Why?
| | Radiography, Interventional | 1 | 2000 | 105 | 0.160 |
Why?
| | Clinical Coding | 1 | 2019 | 19 | 0.160 |
Why?
| | Consolidation Chemotherapy | 1 | 2019 | 9 | 0.160 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2020 | 67 | 0.160 |
Why?
| | Patient Care Planning | 1 | 2000 | 138 | 0.160 |
Why?
| | Genital Neoplasms, Female | 1 | 2000 | 70 | 0.160 |
Why?
| | Epidermal Growth Factor | 2 | 1998 | 160 | 0.160 |
Why?
| | Image Processing, Computer-Assisted | 3 | 2019 | 684 | 0.160 |
Why?
| | Aquaporin 4 | 1 | 2019 | 86 | 0.150 |
Why?
| | Farms | 1 | 2018 | 1 | 0.150 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1998 | 170 | 0.150 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2006 | 1168 | 0.150 |
Why?
| | Policy | 1 | 2019 | 137 | 0.150 |
Why?
| | Karnofsky Performance Status | 3 | 2015 | 36 | 0.150 |
Why?
| | Risk Factors | 7 | 2016 | 8614 | 0.150 |
Why?
| | Organ Size | 3 | 2018 | 434 | 0.150 |
Why?
| | Urinary Bladder | 2 | 2010 | 161 | 0.150 |
Why?
| | Industry | 1 | 2018 | 65 | 0.140 |
Why?
| | Frontal Lobe | 1 | 1998 | 141 | 0.140 |
Why?
| | Health Priorities | 1 | 2017 | 34 | 0.140 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 2 | 2015 | 98 | 0.140 |
Why?
| | Cell Division | 2 | 1997 | 754 | 0.140 |
Why?
| | Multivariate Analysis | 3 | 2019 | 1422 | 0.140 |
Why?
| | Immunity, Cellular | 1 | 2019 | 247 | 0.140 |
Why?
| | Postoperative Care | 2 | 2017 | 223 | 0.140 |
Why?
| | Radiobiology | 3 | 2008 | 4 | 0.140 |
Why?
| | Health Planning | 1 | 2017 | 46 | 0.140 |
Why?
| | Maximum Tolerated Dose | 4 | 2010 | 183 | 0.140 |
Why?
| | Thymus Neoplasms | 1 | 2017 | 20 | 0.140 |
Why?
| | Perioperative Care | 1 | 2018 | 126 | 0.140 |
Why?
| | Thymoma | 1 | 2017 | 29 | 0.140 |
Why?
| | Cause of Death | 2 | 2017 | 362 | 0.140 |
Why?
| | Disease Progression | 7 | 2019 | 2371 | 0.140 |
Why?
| | Consensus Development Conferences, NIH as Topic | 1 | 2016 | 2 | 0.140 |
Why?
| | Preoperative Period | 1 | 2017 | 102 | 0.130 |
Why?
| | Flunarizine | 2 | 1993 | 2 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 193 | 0.130 |
Why?
| | Monitoring, Intraoperative | 1 | 2016 | 38 | 0.130 |
Why?
| | Health Expenditures | 1 | 2017 | 172 | 0.130 |
Why?
| | Glioma | 2 | 2010 | 285 | 0.130 |
Why?
| | Pulmonary Atelectasis | 1 | 2015 | 11 | 0.130 |
Why?
| | Precision Medicine | 2 | 2017 | 335 | 0.130 |
Why?
| | Gastrointestinal Tract | 1 | 2018 | 169 | 0.130 |
Why?
| | Oximetry | 1 | 2016 | 79 | 0.130 |
Why?
| | Clinical Competence | 2 | 2022 | 882 | 0.120 |
Why?
| | Salvage Therapy | 4 | 2017 | 127 | 0.120 |
Why?
| | Neurosurgery | 1 | 2015 | 26 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 662 | 0.120 |
Why?
| | Multimodal Imaging | 2 | 2013 | 89 | 0.120 |
Why?
| | Intensive Care Units | 1 | 1999 | 614 | 0.120 |
Why?
| | Drug Administration Schedule | 3 | 2014 | 714 | 0.120 |
Why?
| | Induction Chemotherapy | 2 | 2013 | 56 | 0.120 |
Why?
| | Vaginal Neoplasms | 1 | 1994 | 11 | 0.120 |
Why?
| | Sensitivity and Specificity | 5 | 2016 | 1690 | 0.120 |
Why?
| | Soft Tissue Neoplasms | 1 | 2015 | 89 | 0.120 |
Why?
| | Perineum | 1 | 1994 | 25 | 0.120 |
Why?
| | Health Services Research | 1 | 2017 | 373 | 0.120 |
Why?
| | Quality Control | 5 | 2013 | 143 | 0.120 |
Why?
| | Marital Status | 1 | 2014 | 41 | 0.120 |
Why?
| | Incidence | 3 | 2016 | 2314 | 0.120 |
Why?
| | Maytansine | 1 | 2014 | 13 | 0.120 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 2014 | 9 | 0.120 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2014 | 7 | 0.120 |
Why?
| | Nuclear Medicine | 1 | 2014 | 7 | 0.120 |
Why?
| | Prostate | 1 | 2015 | 157 | 0.120 |
Why?
| | Risk | 3 | 2016 | 810 | 0.120 |
Why?
| | Takayasu Arteritis | 1 | 1994 | 8 | 0.110 |
Why?
| | Brain Edema | 1 | 2014 | 59 | 0.110 |
Why?
| | Cerebrovascular Circulation | 1 | 2016 | 219 | 0.110 |
Why?
| | Radiotherapy Setup Errors | 1 | 2013 | 3 | 0.110 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 16 | 0.110 |
Why?
| | Health Status Disparities | 1 | 2016 | 200 | 0.110 |
Why?
| | Cell Survival | 3 | 2008 | 1014 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1142 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2015 | 1204 | 0.110 |
Why?
| | Piperidines | 2 | 2015 | 159 | 0.110 |
Why?
| | Oropharyngeal Neoplasms | 1 | 1994 | 39 | 0.110 |
Why?
| | Erythrocytes | 2 | 2001 | 568 | 0.110 |
Why?
| | Xerostomia | 1 | 1993 | 19 | 0.110 |
Why?
| | Blood Viscosity | 1 | 1993 | 14 | 0.110 |
Why?
| | Observer Variation | 1 | 2014 | 298 | 0.110 |
Why?
| | Calcium | 2 | 1998 | 1089 | 0.110 |
Why?
| | Health Care Reform | 1 | 2014 | 92 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2015 | 268 | 0.110 |
Why?
| | Lactates | 1 | 1993 | 78 | 0.110 |
Why?
| | Early Detection of Cancer | 1 | 2016 | 305 | 0.100 |
Why?
| | Healthcare Disparities | 1 | 2018 | 479 | 0.100 |
Why?
| | Physicians | 1 | 2020 | 765 | 0.100 |
Why?
| | Age Factors | 2 | 2021 | 2885 | 0.100 |
Why?
| | Radiology | 1 | 2014 | 137 | 0.100 |
Why?
| | Colorado | 5 | 2015 | 4090 | 0.100 |
Why?
| | Partial Pressure | 2 | 2002 | 30 | 0.100 |
Why?
| | Biomedical Research | 1 | 2017 | 582 | 0.100 |
Why?
| | Motion | 2 | 2011 | 92 | 0.100 |
Why?
| | Organ Specificity | 2 | 2021 | 266 | 0.100 |
Why?
| | Oxytocin | 1 | 1992 | 45 | 0.100 |
Why?
| | Cardiac Surgical Procedures | 1 | 2016 | 414 | 0.100 |
Why?
| | Hepatic Veins | 1 | 2011 | 29 | 0.090 |
Why?
| | Remission Induction | 3 | 2008 | 233 | 0.090 |
Why?
| | Eponyms | 1 | 1991 | 1 | 0.090 |
Why?
| | Esophageal Neoplasms | 2 | 2008 | 270 | 0.090 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2009 | 97 | 0.090 |
Why?
| | Esophagectomy | 1 | 1992 | 110 | 0.090 |
Why?
| | Computer Simulation | 3 | 2012 | 873 | 0.090 |
Why?
| | Young Adult | 9 | 2018 | 10444 | 0.090 |
Why?
| | Delphi Technique | 2 | 2022 | 157 | 0.090 |
Why?
| | Burkitt Lymphoma | 1 | 1991 | 52 | 0.090 |
Why?
| | Keratin-18 | 1 | 2010 | 10 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 4595 | 0.090 |
Why?
| | Automation | 2 | 2020 | 74 | 0.090 |
Why?
| | Neoplasm, Residual | 1 | 2010 | 104 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 660 | 0.080 |
Why?
| | Meningeal Neoplasms | 2 | 2021 | 86 | 0.080 |
Why?
| | Respiration | 2 | 2023 | 180 | 0.080 |
Why?
| | History, 20th Century | 2 | 2006 | 265 | 0.080 |
Why?
| | Radiation Dosage | 3 | 2019 | 133 | 0.080 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2010 | 52 | 0.080 |
Why?
| | Catheter Ablation | 1 | 2012 | 287 | 0.080 |
Why?
| | Immobilization | 2 | 2010 | 42 | 0.080 |
Why?
| | Caspase 3 | 1 | 2010 | 234 | 0.080 |
Why?
| | Risk Management | 2 | 2020 | 89 | 0.080 |
Why?
| | Sex Factors | 1 | 2014 | 1706 | 0.080 |
Why?
| | Anthracyclines | 1 | 2009 | 42 | 0.080 |
Why?
| | Thoracic Wall | 1 | 2009 | 15 | 0.080 |
Why?
| | Rib Fractures | 1 | 2009 | 25 | 0.080 |
Why?
| | Neuroblastoma | 1 | 2010 | 133 | 0.080 |
Why?
| | Feasibility Studies | 4 | 2016 | 735 | 0.080 |
Why?
| | Chest Pain | 1 | 2009 | 82 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2009 | 686 | 0.080 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2009 | 110 | 0.080 |
Why?
| | Cross-Priming | 1 | 2008 | 18 | 0.070 |
Why?
| | Lymphocyte Count | 1 | 2008 | 132 | 0.070 |
Why?
| | Pharyngeal Neoplasms | 1 | 2007 | 3 | 0.070 |
Why?
| | Carcinoembryonic Antigen | 1 | 2008 | 38 | 0.070 |
Why?
| | Treatment Failure | 4 | 2014 | 330 | 0.070 |
Why?
| | Bile Duct Diseases | 1 | 2008 | 15 | 0.070 |
Why?
| | Carcinoma, Merkel Cell | 1 | 2008 | 17 | 0.070 |
Why?
| | Ki-67 Antigen | 1 | 2008 | 102 | 0.070 |
Why?
| | Statistics, Nonparametric | 2 | 2018 | 384 | 0.070 |
Why?
| | Malaria Vaccines | 1 | 2007 | 6 | 0.070 |
Why?
| | Pancreatic Neoplasms | 1 | 2014 | 721 | 0.070 |
Why?
| | Software | 1 | 2012 | 527 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2010 | 2698 | 0.070 |
Why?
| | Hemocyanins | 1 | 2007 | 55 | 0.070 |
Why?
| | Laryngeal Neoplasms | 1 | 2007 | 27 | 0.070 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2008 | 48 | 0.070 |
Why?
| | Photons | 1 | 2008 | 57 | 0.070 |
Why?
| | Cholestasis, Intrahepatic | 1 | 2008 | 39 | 0.070 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 907 | 0.070 |
Why?
| | Fluorouracil | 1 | 2008 | 152 | 0.070 |
Why?
| | Deoxycytidine | 1 | 2008 | 138 | 0.070 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2008 | 154 | 0.070 |
Why?
| | Mouth Neoplasms | 1 | 2007 | 70 | 0.070 |
Why?
| | Accreditation | 2 | 2022 | 76 | 0.070 |
Why?
| | DNA Repair | 1 | 2008 | 184 | 0.070 |
Why?
| | Quality Assurance, Health Care | 1 | 2009 | 308 | 0.070 |
Why?
| | Antigen Presentation | 1 | 2007 | 188 | 0.070 |
Why?
| | Urinary Tract | 1 | 2006 | 35 | 0.070 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 309 | 0.070 |
Why?
| | Reproducibility of Results | 4 | 2016 | 2764 | 0.070 |
Why?
| | Postoperative Nausea and Vomiting | 1 | 2006 | 10 | 0.070 |
Why?
| | Oligopeptides | 1 | 2008 | 234 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2007 | 206 | 0.070 |
Why?
| | Hodgkin Disease | 1 | 2008 | 121 | 0.060 |
Why?
| | Whole Body Imaging | 1 | 2006 | 19 | 0.060 |
Why?
| | Cisplatin | 2 | 2011 | 262 | 0.060 |
Why?
| | DNA Damage | 1 | 2008 | 351 | 0.060 |
Why?
| | Intestines | 1 | 2009 | 325 | 0.060 |
Why?
| | Vertigo | 1 | 2006 | 37 | 0.060 |
Why?
| | Heart Diseases | 1 | 2009 | 329 | 0.060 |
Why?
| | Cranial Nerve Diseases | 1 | 2006 | 42 | 0.060 |
Why?
| | Physics | 4 | 2010 | 17 | 0.060 |
Why?
| | Heart | 2 | 2020 | 613 | 0.060 |
Why?
| | History, 21st Century | 1 | 2006 | 160 | 0.060 |
Why?
| | Kidney | 2 | 2010 | 1182 | 0.060 |
Why?
| | Light | 1 | 2008 | 336 | 0.060 |
Why?
| | Immunotherapy | 1 | 2009 | 473 | 0.060 |
Why?
| | Brain | 3 | 2022 | 2355 | 0.060 |
Why?
| | Cell Proliferation | 2 | 2010 | 2173 | 0.060 |
Why?
| | Medical Records | 3 | 2010 | 153 | 0.060 |
Why?
| | Pilot Projects | 2 | 2001 | 1360 | 0.060 |
Why?
| | Receptor, ErbB-2 | 2 | 2019 | 300 | 0.060 |
Why?
| | Adolescent | 6 | 2018 | 17800 | 0.060 |
Why?
| | Bevacizumab | 2 | 2015 | 114 | 0.060 |
Why?
| | Interferon-gamma | 1 | 2007 | 719 | 0.060 |
Why?
| | Body Burden | 1 | 2003 | 5 | 0.060 |
Why?
| | Cell Count | 2 | 1995 | 303 | 0.060 |
Why?
| | Maximum Allowable Concentration | 1 | 2003 | 14 | 0.060 |
Why?
| | Costs and Cost Analysis | 2 | 2001 | 196 | 0.060 |
Why?
| | Abdomen | 1 | 2023 | 99 | 0.050 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 239 | 0.050 |
Why?
| | Forecasting | 2 | 2017 | 331 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2009 | 1257 | 0.050 |
Why?
| | Vasopressins | 2 | 1993 | 56 | 0.050 |
Why?
| | Certification | 2 | 2015 | 84 | 0.050 |
Why?
| | Research Design | 2 | 2018 | 919 | 0.050 |
Why?
| | Peptides | 1 | 2007 | 848 | 0.050 |
Why?
| | Electrodes | 1 | 2022 | 99 | 0.050 |
Why?
| | Comorbidity | 2 | 2017 | 1447 | 0.050 |
Why?
| | Pulmonary Gas Exchange | 1 | 2002 | 117 | 0.050 |
Why?
| | Parotid Gland | 1 | 2001 | 24 | 0.050 |
Why?
| | Mastectomy | 1 | 2022 | 99 | 0.050 |
Why?
| | Oxygen Consumption | 2 | 2016 | 587 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-raf | 2 | 1998 | 43 | 0.050 |
Why?
| | Rats | 3 | 2002 | 4913 | 0.050 |
Why?
| | Apoptosis | 1 | 2010 | 2349 | 0.050 |
Why?
| | Hepatitis B | 1 | 2001 | 51 | 0.050 |
Why?
| | Carboplatin | 2 | 2011 | 135 | 0.040 |
Why?
| | Probability | 1 | 2001 | 286 | 0.040 |
Why?
| | Skull Neoplasms | 1 | 2000 | 22 | 0.040 |
Why?
| | Camptothecin | 2 | 2011 | 96 | 0.040 |
Why?
| | Alveolar Process | 1 | 2000 | 5 | 0.040 |
Why?
| | Maxilla | 1 | 2000 | 29 | 0.040 |
Why?
| | Patient Positioning | 1 | 2020 | 41 | 0.040 |
Why?
| | Hospitals, Community | 1 | 2000 | 45 | 0.040 |
Why?
| | Palate | 1 | 2000 | 28 | 0.040 |
Why?
| | Canada | 1 | 2021 | 320 | 0.040 |
Why?
| | Mouth Mucosa | 1 | 2000 | 79 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2008 | 1175 | 0.040 |
Why?
| | Meningioma | 1 | 2000 | 76 | 0.040 |
Why?
| | Enzyme Activation | 2 | 1998 | 771 | 0.040 |
Why?
| | Ontario | 1 | 1999 | 77 | 0.040 |
Why?
| | APACHE | 1 | 1999 | 58 | 0.040 |
Why?
| | Dexamethasone | 2 | 2012 | 316 | 0.040 |
Why?
| | Health Care Rationing | 1 | 1999 | 45 | 0.040 |
Why?
| | Europe | 1 | 2020 | 332 | 0.040 |
Why?
| | Workflow | 1 | 2020 | 132 | 0.040 |
Why?
| | Lymphopenia | 1 | 2019 | 49 | 0.040 |
Why?
| | Fibrosarcoma | 1 | 1999 | 20 | 0.040 |
Why?
| | Reoperation | 2 | 2012 | 513 | 0.040 |
Why?
| | Hepatitis C | 1 | 2001 | 218 | 0.040 |
Why?
| | Neutropenia | 1 | 2019 | 123 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2019 | 292 | 0.040 |
Why?
| | Egtazic Acid | 1 | 1998 | 40 | 0.040 |
Why?
| | Cell Line | 2 | 2008 | 2629 | 0.040 |
Why?
| | Safety | 1 | 2000 | 298 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 366 | 0.040 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1998 | 151 | 0.040 |
Why?
| | Triage | 1 | 2020 | 197 | 0.040 |
Why?
| | Fatal Outcome | 1 | 1998 | 281 | 0.040 |
Why?
| | Immune System | 1 | 2019 | 171 | 0.040 |
Why?
| | Tyrphostins | 1 | 1997 | 13 | 0.040 |
Why?
| | Neurosurgeons | 1 | 2017 | 13 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2000 | 405 | 0.040 |
Why?
| | Patient Admission | 1 | 1999 | 175 | 0.040 |
Why?
| | Headache | 1 | 1998 | 132 | 0.040 |
Why?
| | Tumor Cells, Cultured | 2 | 1997 | 845 | 0.040 |
Why?
| | Lymphocytes | 1 | 2019 | 327 | 0.040 |
Why?
| | Medicaid | 1 | 2021 | 404 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 1999 | 218 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 247 | 0.030 |
Why?
| | Curriculum | 1 | 2022 | 813 | 0.030 |
Why?
| | Program Evaluation | 1 | 2021 | 820 | 0.030 |
Why?
| | Protein Kinase C | 1 | 1998 | 271 | 0.030 |
Why?
| | Syndrome | 2 | 2008 | 330 | 0.030 |
Why?
| | Movement | 2 | 2010 | 242 | 0.030 |
Why?
| | Biopsy | 1 | 2000 | 1024 | 0.030 |
Why?
| | Neurosurgical Procedures | 1 | 2017 | 150 | 0.030 |
Why?
| | Contrast Media | 1 | 1998 | 347 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2016 | 105 | 0.030 |
Why?
| | Abdominal Neoplasms | 1 | 2015 | 26 | 0.030 |
Why?
| | Mutation | 2 | 2019 | 3338 | 0.030 |
Why?
| | Seizures | 1 | 1998 | 337 | 0.030 |
Why?
| | Rats, Inbred F344 | 2 | 1993 | 241 | 0.030 |
Why?
| | Causality | 1 | 2016 | 104 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2006 | 2122 | 0.030 |
Why?
| | Patient Education as Topic | 2 | 2010 | 666 | 0.030 |
Why?
| | Ions | 1 | 2015 | 59 | 0.030 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2016 | 138 | 0.030 |
Why?
| | Medically Uninsured | 1 | 2016 | 122 | 0.030 |
Why?
| | Carbazoles | 1 | 2015 | 76 | 0.030 |
Why?
| | Age Distribution | 1 | 2016 | 341 | 0.030 |
Why?
| | Communication | 1 | 2020 | 734 | 0.030 |
Why?
| | Sulfones | 1 | 2015 | 97 | 0.030 |
Why?
| | Myocardium | 1 | 2020 | 911 | 0.030 |
Why?
| | Length of Stay | 1 | 1999 | 957 | 0.030 |
Why?
| | Doxorubicin | 2 | 2008 | 286 | 0.030 |
Why?
| | Netherlands | 1 | 2014 | 64 | 0.030 |
Why?
| | Vital Capacity | 1 | 2015 | 254 | 0.030 |
Why?
| | North Carolina | 1 | 2014 | 83 | 0.030 |
Why?
| | Neutrophils | 1 | 2019 | 1089 | 0.030 |
Why?
| | Sigmoid Neoplasms | 1 | 1994 | 3 | 0.030 |
Why?
| | Critical Illness | 1 | 1999 | 640 | 0.030 |
Why?
| | Texas | 1 | 2014 | 188 | 0.030 |
Why?
| | Models, Statistical | 1 | 2018 | 595 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2018 | 513 | 0.030 |
Why?
| | Trastuzumab | 1 | 2014 | 89 | 0.030 |
Why?
| | Forced Expiratory Volume | 1 | 2015 | 471 | 0.030 |
Why?
| | Spatial Analysis | 1 | 2013 | 20 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1080 | 0.030 |
Why?
| | Erythrocyte Deformability | 1 | 1993 | 12 | 0.030 |
Why?
| | Choice Behavior | 1 | 2014 | 150 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2013 | 136 | 0.030 |
Why?
| | Animals | 5 | 2010 | 31565 | 0.030 |
Why?
| | Cell Cycle | 1 | 1995 | 541 | 0.030 |
Why?
| | Medical Errors | 1 | 2013 | 86 | 0.030 |
Why?
| | Rheology | 1 | 1993 | 86 | 0.030 |
Why?
| | Regression Analysis | 1 | 2015 | 945 | 0.030 |
Why?
| | Fiducial Markers | 1 | 2012 | 8 | 0.030 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 1992 | 64 | 0.020 |
Why?
| | Neurophysins | 1 | 1992 | 5 | 0.020 |
Why?
| | Arginine Vasopressin | 1 | 1992 | 46 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 1992 | 187 | 0.020 |
Why?
| | Genomics | 1 | 2016 | 633 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2384 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1993 | 507 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1331 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 1992 | 155 | 0.020 |
Why?
| | Lactic Acid | 1 | 1993 | 272 | 0.020 |
Why?
| | Protein Precursors | 1 | 1992 | 119 | 0.020 |
Why?
| | Patient Participation | 1 | 2014 | 348 | 0.020 |
Why?
| | Etoposide | 1 | 2011 | 149 | 0.020 |
Why?
| | Fibrosis | 1 | 2013 | 452 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3003 | 0.020 |
Why?
| | Africa | 1 | 1991 | 92 | 0.020 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 1 | 2010 | 12 | 0.020 |
Why?
| | Retreatment | 1 | 2010 | 67 | 0.020 |
Why?
| | Amino Acid Chloromethyl Ketones | 1 | 2010 | 23 | 0.020 |
Why?
| | United Kingdom | 1 | 1991 | 226 | 0.020 |
Why?
| | Carmustine | 1 | 2010 | 47 | 0.020 |
Why?
| | Paclitaxel | 1 | 2011 | 190 | 0.020 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2010 | 45 | 0.020 |
Why?
| | Vincristine | 1 | 2010 | 98 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2010 | 119 | 0.020 |
Why?
| | Palliative Care | 2 | 2012 | 641 | 0.020 |
Why?
| | Caspase Inhibitors | 1 | 2010 | 77 | 0.020 |
Why?
| | Immunoblotting | 1 | 2010 | 282 | 0.020 |
Why?
| | Physical Phenomena | 2 | 1999 | 12 | 0.020 |
Why?
| | Kinetics | 1 | 1993 | 1547 | 0.020 |
Why?
| | Lymphatic Irradiation | 1 | 2009 | 9 | 0.020 |
Why?
| | Logistic Models | 1 | 2014 | 1829 | 0.020 |
Why?
| | Urination Disorders | 1 | 2009 | 11 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 1997 | 2537 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 211 | 0.020 |
Why?
| | Cystitis | 1 | 2009 | 20 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2013 | 926 | 0.020 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2008 | 11 | 0.020 |
Why?
| | Ipilimumab | 1 | 2009 | 27 | 0.020 |
Why?
| | Nephrectomy | 1 | 2010 | 149 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2010 | 135 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 445 | 0.020 |
Why?
| | RNA Interference | 1 | 2010 | 431 | 0.020 |
Why?
| | Smoking | 1 | 2015 | 1382 | 0.020 |
Why?
| | Premedication | 1 | 2008 | 36 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 725 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 45 | 0.020 |
Why?
| | Models, Animal | 1 | 2010 | 340 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 787 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 80 | 0.020 |
Why?
| | Hemodynamics | 1 | 1992 | 1015 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2007 | 33 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2008 | 214 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1143 | 0.020 |
Why?
| | Forearm | 1 | 2008 | 112 | 0.020 |
Why?
| | HIV Infections | 1 | 2001 | 2453 | 0.020 |
Why?
| | Prednisone | 1 | 2008 | 229 | 0.020 |
Why?
| | Diarrhea | 1 | 2008 | 170 | 0.020 |
Why?
| | Pain Measurement | 1 | 2009 | 441 | 0.020 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2007 | 59 | 0.020 |
Why?
| | Medical History Taking | 1 | 2007 | 115 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2010 | 445 | 0.020 |
Why?
| | Tomography, Spiral Computed | 1 | 2006 | 23 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2010 | 526 | 0.020 |
Why?
| | Cognition | 1 | 2013 | 990 | 0.020 |
Why?
| | Pedigree | 1 | 2007 | 460 | 0.020 |
Why?
| | Epitopes | 1 | 2008 | 434 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2010 | 489 | 0.020 |
Why?
| | Cells, Cultured | 1 | 1993 | 3861 | 0.020 |
Why?
| | Antiemetics | 1 | 2005 | 32 | 0.020 |
Why?
| | Spinal Cord Neoplasms | 1 | 2004 | 36 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2008 | 1981 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1993 | 3498 | 0.010 |
Why?
| | Testosterone | 1 | 2007 | 341 | 0.010 |
Why?
| | Esthetics | 1 | 2003 | 37 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 2783 | 0.010 |
Why?
| | Mastectomy, Segmental | 1 | 2003 | 76 | 0.010 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2003 | 49 | 0.010 |
Why?
| | Spinal Cord | 1 | 2005 | 344 | 0.010 |
Why?
| | Carcinoma, Lobular | 1 | 2003 | 44 | 0.010 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2003 | 76 | 0.010 |
Why?
| | Signal Transduction | 2 | 2010 | 4501 | 0.010 |
Why?
| | Craniotomy | 1 | 2000 | 68 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 2000 | 175 | 0.010 |
Why?
| | Iridium Radioisotopes | 1 | 1999 | 4 | 0.010 |
Why?
| | Skull | 1 | 2000 | 119 | 0.010 |
Why?
| | Antisickling Agents | 1 | 1999 | 5 | 0.010 |
Why?
| | Cobalt Radioisotopes | 1 | 1999 | 6 | 0.010 |
Why?
| | Surgical Flaps | 1 | 2000 | 121 | 0.010 |
Why?
| | Tumor Stem Cell Assay | 1 | 1999 | 33 | 0.010 |
Why?
| | Oxyhemoglobins | 1 | 1999 | 20 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 2000 | 438 | 0.010 |
Why?
| | Allosteric Regulation | 1 | 1999 | 81 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 1999 | 242 | 0.010 |
Why?
| | Phosphotyrosine | 1 | 1997 | 33 | 0.010 |
Why?
| | Inositol 1,4,5-Trisphosphate | 1 | 1997 | 27 | 0.010 |
Why?
| | Phospholipase C gamma | 1 | 1997 | 26 | 0.010 |
Why?
| | Type C Phospholipases | 1 | 1997 | 65 | 0.010 |
Why?
| | Radiation, Ionizing | 1 | 1997 | 71 | 0.010 |
Why?
| | Nitriles | 1 | 1997 | 149 | 0.010 |
Why?
| | Hemoglobins | 1 | 1999 | 308 | 0.010 |
Why?
| | Pulmonary Circulation | 1 | 1999 | 407 | 0.010 |
Why?
| | Isoenzymes | 1 | 1997 | 283 | 0.010 |
Why?
| | Bronchial Neoplasms | 1 | 1995 | 13 | 0.010 |
Why?
| | Child | 2 | 2008 | 18400 | 0.010 |
Why?
| | Child, Preschool | 1 | 2008 | 9114 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 1997 | 743 | 0.010 |
Why?
| | Endometrial Neoplasms | 1 | 1995 | 141 | 0.010 |
Why?
| | Postoperative Period | 1 | 1994 | 288 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1992 | 227 | 0.010 |
Why?
| | Microcirculation | 1 | 1992 | 133 | 0.010 |
Why?
| | Mice | 1 | 1999 | 14841 | 0.000 |
Why?
|
|
Kavanagh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|